Natera 배당금 및 환매

배당금 기준 확인 0/6

Natera 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

-0.1%

환매 수익률

총 주주 수익률	-0.1%
미래 배당 수익률	0%
배당금 성장	n/a
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
지급 비율	n/a

최근 배당금 및 환매 업데이트

업데이트 없음

Recent updates

Subdued Growth No Barrier To Natera, Inc. (NASDAQ:NTRA) With Shares Advancing 25%

Nov 19

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$158

Nov 15

Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds

Oct 31

Natera, Inc.'s (NASDAQ:NTRA) Intrinsic Value Is Potentially 20% Below Its Share Price

Sep 18

Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?

Jul 05

Natera: Overdue For A Breather

Jun 03

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119

May 12

Natera, Inc. (NASDAQ:NTRA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Aug 07

Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?

May 16

Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement

Apr 18

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 NTRA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: NTRA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Natera 시장 대비 배당 수익률

NTRA 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (NTRA)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.2%
업계 평균 (Biotechs)	2.3%
애널리스트 예측 (NTRA) (최대 3년)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 NTRA 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 NTRA 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 NTRA 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: NTRA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Natera 배당금 및 환매

배당금 기준 확인 0/6

주요 정보

최근 배당금 및 환매 업데이트

Recent updates

Independent Director recently sold US$1.5m worth of stock

Independent Director exercised options and sold US$4.6m worth of stock

Subdued Growth No Barrier To Natera, Inc. (NASDAQ:NTRA) With Shares Advancing 25%

No longer forecast to breakeven

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$158

Co-Founder & Director notifies of intention to sell stock

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Natera Announces Completion of Signatera Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer

Natera, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds

Now 22% overvalued after recent price rise

Co-Founder & Director notifies of intention to sell stock

Natera, Inc.'s (NASDAQ:NTRA) Intrinsic Value Is Potentially 20% Below Its Share Price

Natera, Inc. Announces New Data from the GALAXY Arm of the Ongoing Circulate-Japan Trial at the 2024 Congress of the European Society for Medical Oncology in Barcelona, Spain

Now 23% overvalued after recent price rise

Consensus estimates of losses per share improve by 20%

Forecast to breakeven in 2026

Co-Founder & Executive Chairman exercised options to buy US$22m worth of stock.

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2026

Natera, Inc. to Report Q2, 2024 Results on Aug 08, 2024

CEO & Director notifies of intention to sell stock

Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?

Natera, Inc. Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer

CEO & Director notifies of intention to sell stock

Natera, Inc. Launches Differentiated New Feature for Prospera Heart Test, Enhancing Detection of Rejection for Transplant Patients

Natera: Overdue For A Breather

New minor risk - Insider selling

Secretary & Chief Legal Officer notifies of intention to sell stock

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119

Price target increased by 9.0% to US$113

Natera, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$0.56 loss per share (vs US$1.23 loss in 1Q 2023)

Natera, Inc. to Report Q1, 2024 Results on May 09, 2024

Natera, Inc., Annual General Meeting, Jun 12, 2024

CEO & Director notifies of intention to sell stock

Now 20% undervalued

Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation

Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (Modern) A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer

Is There An Opportunity With Natera, Inc.'s (NASDAQ:NTRA) 41% Undervaluation?

Natera: Capitalizing On The Positive Momentum Of Personalized Medicine

Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™? in Stage II Colorectal Cancer

CEO & Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 11%

Is Natera (NASDAQ:NTRA) A Risky Investment?

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 12% to US$86.94

Natera, Inc. Provides Earnings Guidance for the Year 2024

Natera, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Independent Director notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Natera, Inc. Announces New Study Demonstrates Signatera's Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. Provides Update on Ravgen Trial

Natera, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2023

Natera Announces New Study Highlighting the Benefits of Signatera's Unique Method of Quantifying ctDNA

Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA)

Natera, Inc. Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023

Natera, Inc. Raises Revenue Guidance for the Full Year 2023

Is Natera (NASDAQ:NTRA) A Risky Investment?

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Natera, Inc. Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer

Natera's RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight in Chronic Kidney Disease

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. Announces Updated Data from the Galaxy Arm of the Circulate-Japan Trial

Natera, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Natera, Inc. to Present New Signatera MRD Data At ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study

Natera, Inc. Announces New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early

Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera

Natera, Inc. Announces Senior Leadership Appointments

Natera, Inc. Announces Expanded I-Spy 2 Collaboration to Evaluate Signatera™? for Breast Cancer Patients in the Neoadjuvant Setting

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $250.25 million.

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $250.25 million.